Wellington Management Group LLP Decreases Stake in Illumina, Inc. (NASDAQ:ILMN)

Wellington Management Group LLP cut its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 18.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 25,298 shares of the life sciences company's stock after selling 5,648 shares during the period. Wellington Management Group LLP's holdings in Illumina were worth $3,381,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Janney Montgomery Scott LLC increased its holdings in Illumina by 32.4% in the fourth quarter. Janney Montgomery Scott LLC now owns 8,710 shares of the life sciences company's stock worth $1,164,000 after purchasing an additional 2,130 shares in the last quarter. Blue Trust Inc. grew its position in shares of Illumina by 17.4% during the 4th quarter. Blue Trust Inc. now owns 1,037 shares of the life sciences company's stock worth $135,000 after buying an additional 154 shares during the period. Caprock Group LLC increased its stake in shares of Illumina by 3.7% in the 4th quarter. Caprock Group LLC now owns 2,992 shares of the life sciences company's stock valued at $400,000 after acquiring an additional 108 shares in the last quarter. Chicago Partners Investment Group LLC acquired a new position in shares of Illumina during the 4th quarter valued at $216,000. Finally, Tokio Marine Asset Management Co. Ltd. boosted its stake in Illumina by 9.3% during the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,440 shares of the life sciences company's stock worth $727,000 after acquiring an additional 462 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Illumina

In related news, CFO Ankur Dhingra bought 6,100 shares of the company's stock in a transaction on Monday, May 12th. The shares were purchased at an average cost of $81.21 per share, for a total transaction of $495,381.00. Following the completion of the purchase, the chief financial officer now directly owns 24,906 shares in the company, valued at $2,022,616.26. The trade was a 32.44% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 2.60% of the company's stock.

Illumina Stock Up 0.5%

ILMN stock traded up $0.41 during trading on Friday, reaching $82.66. The stock had a trading volume of 1,614,255 shares, compared to its average volume of 2,288,830. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $13.09 billion, a price-to-earnings ratio of -10.76, a P/E/G ratio of 1.60 and a beta of 1.32. Illumina, Inc. has a one year low of $68.70 and a one year high of $156.66. The company's 50 day moving average is $77.90 and its two-hundred day moving average is $104.30.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share for the quarter, topping analysts' consensus estimates of $0.96 by $0.01. The firm had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.03 billion. Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. The company's revenue was down 1.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.98 EPS. Equities research analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Wall Street Analysts Forecast Growth

ILMN has been the subject of a number of research reports. Stephens restated an "overweight" rating and issued a $105.00 price target on shares of Illumina in a report on Tuesday, May 20th. JPMorgan Chase & Co. reduced their target price on Illumina from $120.00 to $85.00 and set a "neutral" rating for the company in a research note on Friday, May 9th. Hsbc Global Res downgraded Illumina from a "strong-buy" rating to a "hold" rating in a report on Friday, February 28th. Morgan Stanley lowered their target price on Illumina from $136.00 to $100.00 and set an "equal weight" rating on the stock in a research report on Monday, May 12th. Finally, Citigroup reduced their price target on shares of Illumina from $90.00 to $85.00 and set a "neutral" rating for the company in a research report on Monday, April 7th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $128.84.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.